Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / EDRN Pre-Validation of Multiplex Biomarker in Urine

EDRN Pre-Validation of Multiplex Biomarker in Urine

199
Chinnaiyan, Arul M.University of Michigan

No involved investigator sites defined.

CEACAM5
UNKNOWN
Prostate and Urologic Cancers Research Group

The goal of this proposal is to begin to establish an EDRN “pre-validation” trial of a multiplex set of transcripts, including the ETS gene fusions, in post-DRE urine sediments. As can be evidenced by our preliminary data, we have established the utility of this multiplex urine test (which includes TMPRSS-ERG, SPINK1, PCA3 and GOLPH2) in a cohort of prospectively collected urine sediments from the University of Michigan EDRN CEVC site (collected by co-I, Dr. John Wei). In this proposal, we will run this multiplex assay on prospectively collected post-DRE urines collected from other EDRN sites. The idea is to couple this “pre-validation” study with an EDRN validation trial under consideration for the Gen-Probe PCA3 urine test (directed by Drs. John Wei and Harry Rittenhouse).

To establish an EDRN “pre-validation” trial of a multiplex set of transcripts, including the ETS gene fusions, in post-DRE urine sediments.

No datasets are currently associated with this protocol.


Announcement 04/26/2017

A new funding opportunity associated with the Beau Biden Cancer Moonshot Initiative, Integration and Validation of Emerging Technologies to Accelerate Cancer Research, has been released and is due May 10, 2017. Click here for more information.

Announcement 03/14/2017

Thank you to everyone who made the March 2017 EDRN Steering Committee Meeting a success. The next EDRN Steering Committee Meeting will be on September 12-14, 2017, in Seattle, WA.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.